Suraksha Diagnostic Ltd.
NSE: SURAKSHA · Healthcare Service Provider
Snapshot
Unlock Suraksha Diagnostic Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Suraksha Diagnostic Ltd. is a healthcare service provider offering a comprehensive range of pathology and radiology diagnostic services. Established in 1992, the company operates a network of diagnostic centres across West Bengal, Bihar, and the Delhi NCR region.
Business Model
The company generates revenue by providing diagnostic testing and imaging services to patients through its network of centres. It focuses on delivering accurate medical diagnostics under one roof to ensure patient convenience and service quality.
Growth Outlook
The company aims to leverage its established brand presence in Eastern India to expand its footprint further. Continued focus on service accuracy and facility expansion remains the primary driver for its regional growth strategy.
Key Risks
- Regulatory Compliance. The diagnostic industry is subject to stringent healthcare regulations and quality standards that require continuous investment and oversight.
- Intense Competition. The company faces significant competition from both large national diagnostic chains and numerous unorganised local players.
- Technological Obsolescence. Rapid advancements in medical diagnostic technology necessitate frequent capital expenditure to maintain service relevance and accuracy.
- Geographic Concentration. A significant portion of the company's operations is concentrated in Eastern India, making it vulnerable to regional economic or political instability.
Start your research today
Unlock AI insights, financials, peers and live data on Suraksha Diagnostic Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹323 Cr
TTM · consolidated
NET PROFIT
₹36 Cr
TTM · consolidated
EPS
₹7.00
TTM · consolidated
RETURN ON EQUITY
15.8%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
18.6%
TTM · consolidated
P/E
47.5x
Q1 FY27 · consolidated
EV/EBITDA
16.3x
Q1 FY27 · consolidated
EBITDA MARGIN
32.7%
TTM · consolidated
NET PROFIT MARGIN
14.7%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q1 FY27 · consolidated
Peers · Healthcare Service Provider
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Suraksha Diagnostic Ltd.SURAKSHA | ₹1,731 Cr | 47.49 | 16.34 | 22.5% | 32.7% | 15.8% | 18.6% | +9.8% |
Nephrocare Health ServicesNEPHROPLUS | ₹6,994 Cr | — | — | — | 23.0% | — | — | — |
Krsnaa Diagnostics Ltd.KRSNAA | ₹1,817 Cr | 18.63 | 8.75 | 10.2% | 32.5% | 10.5% | 13.3% | -32.6% |
3B BlackBio Dx Ltd3BBLACKBIO | ₹1,253 Cr | 20.88 | 14.79 | 41.9% | 58.0% | 21.2% | 26.3% | +1.9% |
One Global Service Provider LimitedONEGLOBAL | ₹1,060 Cr | — | — | — | 19.0% | — | — | +107.5% |
Gaudium IVF and Women Health LimitedGAUDIUMIVF | ₹847 Cr | — | — | — | 36.0% | — | — | — |
As of Q1 FY27
Financials
Suraksha Diagnostic Ltd.
NSE: SURAKSHA · Healthcare Service Provider
Snapshot
Unlock Suraksha Diagnostic Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Suraksha Diagnostic Ltd. is a healthcare service provider offering a comprehensive range of pathology and radiology diagnostic services. Established in 1992, the company operates a network of diagnostic centres across West Bengal, Bihar, and the Delhi NCR region.
Business Model
The company generates revenue by providing diagnostic testing and imaging services to patients through its network of centres. It focuses on delivering accurate medical diagnostics under one roof to ensure patient convenience and service quality.
Growth Outlook
The company aims to leverage its established brand presence in Eastern India to expand its footprint further. Continued focus on service accuracy and facility expansion remains the primary driver for its regional growth strategy.
Key Risks
- Regulatory Compliance. The diagnostic industry is subject to stringent healthcare regulations and quality standards that require continuous investment and oversight.
- Intense Competition. The company faces significant competition from both large national diagnostic chains and numerous unorganised local players.
- Technological Obsolescence. Rapid advancements in medical diagnostic technology necessitate frequent capital expenditure to maintain service relevance and accuracy.
- Geographic Concentration. A significant portion of the company's operations is concentrated in Eastern India, making it vulnerable to regional economic or political instability.
Start your research today
Unlock AI insights, financials, peers and live data on Suraksha Diagnostic Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹323 Cr
TTM · consolidated
NET PROFIT
₹36 Cr
TTM · consolidated
EPS
₹7.00
TTM · consolidated
RETURN ON EQUITY
15.8%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
18.6%
TTM · consolidated
P/E
47.5x
Q1 FY27 · consolidated
EV/EBITDA
16.3x
Q1 FY27 · consolidated
EBITDA MARGIN
32.7%
TTM · consolidated
NET PROFIT MARGIN
14.7%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q1 FY27 · consolidated
Peers · Healthcare Service Provider
As of Q1 FY27